Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07042100 · ClinicalTrials.gov registry record · Phase 1
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
A Phase 1 study of Advanced Solid Tumors, sponsored by Sun Pharma Advanced Research Company Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 177
- Enrollment target
- 11
- Study locations
NCT07042100 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 177 participants, below the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (10% lower). The trial reports 11 study locations across 10 states.
The verdict
NCT07042100, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Sun Pharma Advanced Research Company Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 177 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a Phase 1 study of SBO-154 in patients with advanced cancers who are unable to tolerate or have not previously responded to standard therapy available in the country. The study involves multiple doses and takes place at several centers.
Conditions Studied
Interventions
- BIOLOGICAL Dose level (DL)1
- BIOLOGICAL DL2
- BIOLOGICAL DL3
- BIOLOGICAL DL4
- BIOLOGICAL DL5
Study Locations (11)
Maharashtra
- Tata Memorial hospital - Mumbai
- Noble Hospital Pvt. Ltd. - Pune
Arizona
- Honorhealth Research Institute - Scottsdale
California
- Sarcoma Oncology Research Center - Santa Monica
Connecticut
- Yale University - Yale Cancer Center - New Haven
Illinois
- Hope And Healing Cancer Services, Llc - Hinsdale
Texas
- MD Anderson Cancer Center - Houston
New South Wales
- Scientia Clinical Research - Randwick
Queensland
- Sunshine Coast University Private Hospital - Birtinya
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2025-08-12 |
| Est. Completion | 2030-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07042100
The ClinicalTrials.gov registry entry for NCT07042100 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (10% lower). The listed sponsor is Sun Pharma Advanced Research Company Limited, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which Dose level (DL)1 is the first listed.
NCT07042100 reports 11 study locations spanning 10 distinct geographic areas - top geographies include Maharashtra, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT07042100 about?
NCT07042100 is a clinical study titled "A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.". This is a Phase 1 study of SBO-154 in patients with advanced cancers who are unable to tolerate or have not previously responded to standard therapy available in the country. The study involves multiple doses and takes place at several centers.
What is the current status of trial NCT07042100?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 177 participants. The study started on 2025-08-12. Estimated completion is 2030-08.
What conditions does trial NCT07042100 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT07042100?
The interventions under investigation include: Dose level (DL)1 (BIOLOGICAL), DL2 (BIOLOGICAL), DL3 (BIOLOGICAL), DL4 (BIOLOGICAL), DL5 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07042100?
This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07042100 being conducted?
This trial has 11 study locations across Arizona, California, Connecticut, Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.